Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion

NCT06383884 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor, Adult

Interventions

DRUG: Patritumab Deruxtecan

Sponsor

Samsung Medical Center